Nutra Pharma Partners with EuroAmerican IP to Distribute Nyloxin for Sale to Government Agencies
Nutra Pharma is partnering with EuroAmerican IP, LLC to distribute their Over-the-Counter (OTC) pain reliever, Nyloxin® Topical Gel, through EuroAmerican IP's existing Federal Supply Schedule #V797D-40251
January 18, 2018 -- Coral Springs, Florida -- Nutra Pharma Corporation(OTC: NPHC), a biotechnology company marketing Nyloxin® and Pet Pain-AwayTM in the over-the-counter (OTC) pain management market, announced today that they have partnered with EuroAmerican IP, LLC to distribute their Over-the-Counter (OTC) pain reliever, Nyloxin® Topical Gel, through the Federal Supply Schedule (FSS). The successful addition to FSS will make the product available for purchase through the US - General Services Administration (GSA Advantage) website at www.gsaadvantage.gov.
"With the nation focused on the treatment of chronic pain and the reduction of opiate use, especially for veterans, Nyloxin should go a long way to effectively managing chronic pain symptoms for many of our wounded warriors and reducing their use of opiate drugs," stated Rik J Deitsch, CEO of Nutra Pharma. "By partnering with EuroAmerican, we expect to be able to effectively distribute our products directly to various agencies and health departments," he continued. "It is our plan to begin actively marketing Nyloxin Topical Gel through the GSA Advantage to governmental agencies, including the Department of Veterans Affairs, to EuroAmerican's Federal Supply Schedule," he concluded.
The U.S. Department of Defense has been reporting an increase in the use and abuse of prescription medications; particularly opiates. In October, the Federal government declared the opiate epidemic a national public health emergency. But prescription drugs are not the only issue. The most common and seemingly harmless way to treat pain is with non-steroidal, anti-inflammatory drugs (NSAIDS). But these have risks as well. Overuse can cause nausea, vomiting, diarrhea, heartburn, ulcers and internal bleeding. In severe cases chest pain, heart failure, kidney dysfunction and life-threatening allergic reactions can occur. Ibuprofen, also an NSAID, has been of particular concern in the military. The terms "Ranger Candy" and "Military Candy" refer to the service men and women who are said to use 800mg doses of Ibuprofen to control their pain. But when taking anti-inflammatory Ibuprofen in high doses for chronic pain, there is potential for critical health risks; abuse can lead to serious stomach problems, internal bleeding and even kidney failure. There are significantly greater health risks when abuse of this drug is combined with alcohol intake.
Nyloxin® is a safe, non-narcotic, and non-addictive Homeopathic pain reliever clinically proven to treat moderate to severe chronic pain while not impairing cognitive function. Nyloxin® offers several benefits as pain relievers and anti-inflammatory agents. With increasing concern about consumers using opioid and acetaminophen-based pain relievers, Nyloxin® offers an alternative that does not rely on opiates or non-steroidal anti-inflammatory drugs, otherwise known as NSAIDs, for their pain relieving effects. Nyloxin® has a well-defined safety profile. Since the early 1930s, the active pharmaceutical ingredient (API), Asian cobra venom, has been studied in more than 46 human clinical studies.
"We are excited to be working with Nutra Pharma," commented Debra J Paul, CEO, and Tami Dana, COO, of EuroAmerican. "Nyloxin is an exciting alternative to opiate drugs. We believe that it can be a significant tool for combatting opioids in our veterans and in our military," they continued. "We have seen that Nyloxin substantially reduces all types of pain without mental confusion, addiction or toxicity. We believe that we can quickly and successfully add the Nyloxin products to our existing product list for distribution through our Federal Supply Schedule #V797D-40251 to be available as a replacement for opioids and other pain management drugs," they concluded.
About EuroAmerican IP, LLC (EAIP)
EAIP functions as a Small, Woman Owned Business as a Medical Supply Distributor by providing various industries and government facilities with their unique line of products within the medical, health, and outdoor arenas. Their dedicated mission is to distribute reliable, quality products and provide prompt delivery. EAIP proudly participates in the Prime Vendor Program to expand on sales and services throughout the country. For additional information about EuroAmerican IP, visit: www.EuroAmericanProducts.com
About Nutra Pharma Corp.
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. Additionally, the Company markets drug products for sale for the treatment of pain under the brand Nyloxin® and Pet Pain-AwayTM.
For additional information about Nutra Pharma, visit:
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The agreement with EuroAmerican IP, LLC should not be construed as an indication in any way whatsoever of the future value of the Company's common stock or its financial value. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.